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Prostaglandins exert a profound inﬂuence over the adhesive, migratory, and invasive behavior of cells during the development
and progression of cancer. Cyclooxygenase-2 (COX-2) and microsomal prostaglandin E2 synthase-1 (mPGES-1) are upregulated
in inﬂammation and cancer. This results in the production of prostaglandin E2 (PGE2), which binds to and activates G-protein-
coupled prostaglandin E1–4 receptors (EP1–4). Selectively targeting the COX-2/mPGES-1/PGE2/EP1–4 axis of the prostaglandin
pathway can reduce the adhesion, migration, invasion, and angiogenesis. Once stimulated by prostaglandins, cadherin adhesive
connections between epithelial or endothelial cells are lost. This enables cells to invade through the underlying basement
membrane and extracellular matrix (ECM). Interactions with the ECM are mediated by cell surface integrins by “outside-in
signaling” through Src and focal adhesion kinase (FAK) and/or “inside-out signaling” through talins and kindlins. Combining
the use of COX-2/mPGES-1/PGE2/EP1–4 axis-targeted molecules with those targeting cell surface adhesion receptors or their
downstream signaling molecules may enhance cancer therapy.
1.The ProstaglandinPathway
Prostaglandins (PGs) and other eicosanoids are bioactive
lipids that impact normal development, tissue homeostasis,
inﬂammation, and cancer progression [1]. Prostaglandins
are derived from the 20-carbon chain fatty acid, arachidonic
acid (AA) stored in the plasma membrane of cells [2, 3].
As a storage mechanism, dietary AA is coupled to CoA
molecules by acyl-coenzyme A (acyl-CoA) synthetases [4].
In turn, fatty acyltransferases utilize arachidonyl-CoA donor
molecules to insert AA into membrane phospholipids [2,
3]. Membrane phospholipids generally retain AA until an
appropriate stimulus catalyzes its release by phospholipase
A2 [5–8]( Figure 1).
O n c er e l e a s e d ,f r e eA As e r v e sas u b s t r a t ef o rc y c l o o x y -
genases (COX) 1 or 2 (∼72kDa; Figure 1). Cyclooxygenases
are mixed function oxidase enzymes that ﬁrst peroxidate
AA to form a hydroperoxy endoperoxide that links two
oxygen molecules across carbons 9 and 11, prostaglandin G2
(PGG2).Asthesecondcoordinateenzymaticfunction,COXs
reduce a hydroperoxy-group at carbon 15 of PGG2 to form
prostaglandin H2 (PGH2)[ 9, 10]. As a rate-limiting product
in this pathway, PGH2 serves as the substrate for a variety
of PG synthases. These PG synthases include various iso-
forms of prostaglandin D2 (PGD2) synthases (PGDS) [11],
prostaglandin E2 (PGE2) synthases (PGES) [12–16], and
prostaglandin F2α (PGF2α) synthase (PGFS) [17]. PGH2 can
also be synthesized into prostacyclin (PGI2) by its own
separatesynthase[18,19](PGIS)orthromboxaneA2 (TxA2)
by its synthase (TXS) [20]. In the case of inﬂammatory
and carcinogenic activity, increased expression of COX-2
and microsomal PGE synthase-1 (mPGES-1) both occur to
amplify the accumulation of PGE2 in tumors [21–26]. Once
synthesized, prostanoids are transported into the extracellu-
lar microenvironment by speciﬁc multidrug resistance asso-
ciated proteins (MRPs). These MRP molecules contain 12-
transmembrane spanning domains in the plasma membrane
and two cytosolic ATP-binding/hydrolysis sites [27]. Among
these export molecules, MRP4 is a 160kDa protein that acts
as the primary transporter for PGs. Once exported to the
microenvironment, prostanoids bind to G-protein coupled
receptors that contain 7 transmembrane spanning domains.
These PG receptors include DP1, DP2, EP1-4, FP, IP, and
TP that are classiﬁed according to their ligand speciﬁcity2 International Journal of Cell Biology
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Figure 1: Eicosanoid metabolism. Arachidonic acid (AA) is an essential dietary fatty acid that is transported into cells and stored in
membrane phospholipids. First AA is coupled to acyl-CoA by acyl-coenzyme A synthetases (ACLS). Fatty acyltransferases (FACT) then
insert AA into membrane phospholipids. Cytoplasmic phospholipase A2 (cPLA2) releases AA from membrane phospholipids after agonist
stimulation. In turn, free AA is converted to prostaglandin G2 (PGG2) and then prostaglandin H2 (PGH2) by cyclooxygenases (COXs).
PGH2 then becomes a substrate for a variety of PG synthases. These PG synthases are identiﬁed by the speciﬁc prostaglandin each one
produces, namely, PGD2 synthases (PGDSs), PGE2 synthases (PGESs), (PGF2α) synthase (PGFS), PGI2 synthase (PGIS), or TxA2 synthase
(TXS). Both COX-2 and microsomal PGE synthase-1 (mPGES-1) are elevated in tumors. Export involves multidrug resistance-associated
protein 4 (MRP4). In the extracellular milieu, PGs bind to G-protein-coupled receptors identiﬁed as DP1, DP2, EP1-4, FP, IP, and TP.
Among these, EP receptors interact with G-stimulatory (Gs) or G-inhibitory (Gi) proteins stimulating downstream signals such as cAMP,
Ca2+, inositol phosphates or IP3/Ca2+, and Rho. Catabolism involves uptake by PG transporter (PGT) and inactivation by NAD+ dependent
15-hydroxyprostaglandin dehydrogenase (15-PGDH).
[28]. There are four EP receptors that require G-stimulatory
(Gs) or G-inhibitory (Gi) proteins to initiate downstream
signals such as cAMP, Ca2+, and inositol phosphates [29].
More speciﬁcally, EP1 regulates Ca2+ ﬂux; EP2 and EP4
both increase cAMP levels; whereas EP3 decreases cAMP,
increases IP3/Ca2+, and activates Rho. These signaling path-
ways frequently initiate transcription or crosstalk with other
signal transduction pathways [30–32]. Prostaglandins can
also interact with nuclear receptors. Peroxisome proliferator-
activated receptors (PPARs) are nuclear receptors that also
bind PGs and complex with retinoic X receptors (RXRs) to
initiate gene transcription [33, 34]. The catabolism of PG
occurs as a two-step uptake and then inactivation process.
PGs are taken up by a 12 transmembrane domain glycopro-
teinknownasaPGtransporter(PGT)[35–37].AfterPGE2 is
transported across the plasma membrane, it is enzymatically
catabolized by NAD+ dependent 15-hydroxyprostaglandin
dehydrogenase (15-PGDH) causing inactivation [36, 38, 39].
Two NAD+-15-PGDH protein monomers (29kDa) form
enzymatically active complexes by dimerization. Interactions
with biologically active prostaglandins containing hydroxyl
groups at carbon 15 are inactivated by conversion to 15-
keto catabolites. The levels of both PGT and 15-PGDH are
decreased in cancer leading to the accumulation of PGE2
in tumor tissues [35, 36, 39, 40]. The accumulation of
PGE2 in the developing tumor microenvironment promotes
tissue reorganization, angiogenesis, as well as cell adhesion,
migration and invasion through the basement membrane
barrier.
2. ProstaglandinsandCadherins: Making and
Breaking Cell-CellContacts
Prostaglandins play an important role in wound healing
and tissue reorganization [41–46]. The ordered structure
of epithelial and endothelial tissues involves the cadherin
family of molecules [47–51]. In many epithelial and vascular
tissues, prostaglandins inﬂuence the formation and loss ofInternational Journal of Cell Biology 3
cell-cell contacts [52–56]. In vascular tissues for example,
prostaglandins potentiate vascular endothelial VE-cadherin-
dependent cell adhesion [57]. In the case of epithelial
tissues, epithelial E-cadherins are structurally organized into
adherens junctions that form extracellular Ca2+-dependent
transmembrane adhesion complexes between adjacent cells
(Figure 2).
In the cytoplasm of epithelial cells, binding proteins
mediate interactions between the E-cadherin cytoplasmic
domain and the actin cytoskeleton that can trigger a variety
of signaling processes [51, 58–60]. Dynamic analyses have
revealed that α-catenin shuttles between cytoplasmic multi-
proteincomplexesofβ-catenin/E-cadherinoractinﬁlaments
[61]. β-catenin/E-cadherin interactions are regulated by
IQGAPs that are actin-binding scaﬀold proteins [56–58].
IQGAPs interact with Rho GTPases and transmit extracel-
lular signals that inﬂuence morphological and migratory cell
behavior [62–64]. Alternate interactions through δ-catenin
involve p190 and RhoA [65]. Additional adherens junctions
stabilization pathways also exist. One of these pathways
includes the involvement of Src and p140Cap. p140Cap reg-
ulates Src activation by C-terminal Src kinase (Csk) activity
in epithelial-rich tissues that is phosphorylated after cell
matrixadhesion[66–68].Similarly,receptorproteintyrosine
phosphatase mu (PTPμ) has a cell-adhesion molecule-like
extracellular segment and a catalytically active intracellular
segment involved in regulating cell-cell interactions [69, 70].
Nectins-afadin complexes also regulate cell-cell adhesion
cooperativelywithcadherinsandintegrins[71,72].Dynamic
maintenance of cell-cell junctions in epithelial and endothe-
lialtissuesiscriticaltotheirfunctionsaspermeabilityorpro-
tective barriers and their continuous turnover as stress inter-
faces with the surrounding micro- or macro environment.
In order for epithelial cells to migrate, they must break
their adhesive contacts with neighboring cells [56, 73].
The disassembly of cadherin containing adherens junctions
involves internalization through endocytosis that result in
the formation of phagosomes [51]. Internalization occurs by
either caveolin-mediated endocytosis or clathrin-mediated
coated pits [74–76]. Once cadherin-containing phagosomes
are internalized, the extracellular domain resides inside the
vesicles that form. At the same time, β-catenin and Src
that are bound to the cytoplasmic domain of E-cadherin
at the plasma membrane end up on the outside of these
vesicles. Interactions of these vesicles with Ras-related pro-
tein A (RalA) drive cadherin recycling [77]. Interactions
between E-cadherin with Ras-proximate-1/Ras-related pro-
tein 1 (Rap1)-GTPase, E3 ubiquitin ligase followed by ubiq-
uitinization lead to proteosomal degradation [78–80]. Thus,
the internalization and turnover of E-cadherin enables cells
preparing to migrate with the ability to break their adhesive
contacts between adjacent cells.
Breaking adhesive contacts occurs during tissue home-
ostasis, angiogenesis, and cancer progression in vascular or
epithelial tissues and is a very rapid process based on live
cellimaging [49,81,82].Inthecaseofepithelialtissues,their
normal uniform structure typically becomes disorganized
or dysplastic and then anaplastic during cancer progression.
Disorganization in these tissues typically requires breaking
cell-cell junctions maintained by cadherins such as E-cad-
herin [83]. In some cases this is mediated by prostaglandins.
In squamous cell carcinoma, for example, chronically UVir-
radiated SKH-1 mice sequentially lose E-cadherin-mediated
cell-cell contacts as lesions progress from dysplasia to SCCs
[53] (see Table 1). In these studies, the loss of E-cadherin
levelswasinversely associated withincreased PGE2 synthesis.
Furthermore, the loss of E-cadherin involved the EP2 re-
ceptor and was reversed by indomethacin or potentiated by
the EP2 receptor agonist butaprost [53].
Other epithelial tumors exhibit a similar loss of E-
cadherin as COX-2/PGE2 levels increase [84, 85]. This loss of
E-cadherin is often accompanied by an elevation of vimentin
thatisacharacteristicofcellsbecomingmoremigratorydur-
ing epithelial-to-mesenchymal transition (EMT) [86]. This
EMT involving COX-2 is observed in human colon cancers
[87]. The loss of E-cadherin in conjunction with elevations
in COX-2 occurs during the transformation of rat intestinal
epithelial (RIE) cells [88] and during adenoma formation in
ApcMin\+ that exhibit aberrant β-catenin signaling [89]o r
during gastrulation involving the Snail pathway in Zebra
ﬁsh [90]. The COX-2 promoter contains a novel functional
T-cell factor/lymphoid enhancer factor (TCF/LEF) response
element that responds directly to Wnt/β-catenin signaling
[91]. Regulation involving these pathways in some cases may
be reversed. For example, caveolin-1-mediated suppression
of COX-2 can occur via a β-catenin-Tcf/Lef-dependent tran-
scriptionalmechanism[92].Overall,itisbecomingclearthat
tissue homeostasis, reorganization, angiogenesis, and malig-
nant transformation rely on very rapid dynamic making or
breaking of cell-cell junctions centered on cadherin family of
molecules. In most cases, epithelial tissues are strengthened
by the synthesis and deposition of a basement membrane.
3. The Basement Membrane Barrier
Malignancies frequently develop from epithelial precancer-
ous lesions that are initially conﬁned to organ ducts or
the epithelial strata of tissues. The pathologic conversion to
cancerous lesions often involves malignant cells breaching
or invading through the ﬁbrous sheet-like barrier of the
basement membrane (Figure 3)[ 93]. Prostaglandins are
involved in the synthesis, homeostasis, turnover, and struc-
tural reorganization of the basement membrane [94, 95].
The basement membrane underlies the typical cellular epi-
thelium or vascular endothelium and consists of two thin
structural layers. The ﬁrst layer consists of a basal lamina
that is synthesized by epithelial or endothelial cells that diﬀer
in their respective characteristics [96]. The second layer is
the reticular lamina made by ﬁbroblasts, among other sur-
rounding cells [97]. At the electron microscope level, the
basal lamina is subdivided into a clear lamina lucida directly
under the epithelial cells and a structurally opaque lamina
densa [98, 99]. The lamina lucida contains protein and
carbohydrate complexes at the cellular interface consisting of
integrins,laminins(5,6and10),andcollagenXVII,aswellas
typeIVcollagen,laminin1,anddystroglycans[97,100,101].
The lamina densa is a meshwork of type IV collagen ﬁbers,4 International Journal of Cell Biology
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Figure 2: Dynamic adherens junctions. Prostaglandins inﬂuence the assembly, stabilization, and disassembly of cell-cell junctions. E-
cadherins form Ca2+-dependent transmembrane adhesion complexes between adjacent cells (Figure 2). Cytoplasmic regulatory proteins
include α-catenin, β-catenin, IQGAPs scaﬀold proteins that interact with Rho GTPases to alter morphology and migration. Alternate
interactions involve δ-catenin, p190, and RhoA inﬂuencing actin assembly. Together, Src and p140Cap inﬂuence C-terminal Src kinase
(Csk) activity stabilizing cell-cell interactions as well as similar activity by receptor protein tyrosine phosphatase mu (PTPμ). Nectins-
afadin complexes also cooperate with cadherins and integrins to regulate cell-cell adhesion. Disassembly of cadherin complexes involves
either caveolin- or clathrin-mediated endocytosis and phagosome formation. Inside-out vesicles contain cadherin on the inside and β-
catenin and Src exposed to the cytoplasm. When these vesicles interact with Ras-related protein A (RalA), cadherins are recycled. Whereas,
interactions with Ras-proximate-1/Ras-related protein-1-(Rap1-)GTPase and E3 ubiquitin ligase followed by ubiquitinization result in
proteosomal degradation that prepares cells for migration. The loss of E-cadherin in conjunction with elevations in COX-2 occurs during
the transformation and adenoma formation in the presence of Apc mutations causing aberrant β-catenin signaling. Subsequent interactions
with T-cell factor/lymphoid-enhancer-factor-(TCF/LEF-) can cause increases in COX-2 expression.International Journal of Cell Biology 5
Table 1: Prostaglandins in cancer cell adhesion, migration, and invasion summary table.
Adhesive factor Tissue PG Biological eﬀect Refs
Cadherins
↓E-cadherin RIE-S ↑PGE2
COX-2-mediated PGE2 production in rat intestinal epithelial cells (RIE)
downregulates E-cadherin [88]
↓E-cadherin SCC ↑PGE2
Downregulates E-cadherin through the EP2 receptor during squamous cell
carcinoma (SCC) progression [53]
↑E-cadherin NSCLC ↓PGE2
S-valproate and S-diclofenac increased E-cadherin but reduced vimentin and
ZEB1 [84]
↓E-cadherin TCC ↑PGE2
Reciprocal correlation between cyclooxygenase-2 expression and E-cadherin
in human bladder transitional cell carcinoma (TCC). [85, 87]
↑E-cadherin Melanoma ↑PGE2
Decrease of TGFβ1-induced EMT properties in Madin-Darby canine kidney
(MDCK) cells is associated with regaining E-cadherin expression [257]
↑E-cadherin MDCK ↑PGD2
Decrease of TGFβ1-induced EMT properties in MDCK cells is associated with
regaining E-cadherin expression [258]
↓VE-cadherin HLVE ↓PGI2
Inhibition of PGI2-mediated human lung vascular endothelial cell (HLVE)
responses decreased VE-cadherin expression and increased eosinophil
adhesion
[259]
Focal adhesions
↑Actin bundles HeLa ↑PGE2 Examination of cyclooxygenase-dependent actin bundles in HeLa cells. [144]
CREB activation Raw264.7 ↑COX2 Examination of Col-I on the COX-2 expression and the signaling pathways in
macrophages. [145]
↑Focal
adhesions Osteoblasts ↑COX2 Focal adhesion promotes ﬂuid shear stress induction of COX-2 and PGE2
release in osteoblasts
[146–
148]
↑Focal
adhesions 293-EBNA-HEK ↑PGF2α Regulates Rho-mediated morphological changes [150,
151]
Integrins
α2β1 Caco-2 ↑LTD4/↑PGE2 Increased adhesion to collagen I. [177]
β1 HT-29 ↓PGE2 Decreased adhesion and migration on extracellular matrix [178]
α3 Mammary TC ↓PGE2 Decreased adhesion to laminin [179]
α5β1 HLC ↑PGE2 Increased adhesion of human lung carcinoma (HLC) cells to ﬁbronectin [180]
αIIbβ3 B16a melanoma ↑12-HETE Increased adhesion to ﬁbronectin, endothelial cells, and endothelial cell
matrix
[182,
183]
entactin/nidogen-1, as well as perlecan, along with hydrous
polysaccharide-rich gels of heparan sulfate proteoglycans.
The reticular lamina contains collagens I, III, and V that
form a heterogeneous network of ﬁbers and a variety of
proteoglycans [97]. Some basement membrane structures
also contain pores that allow for the passage of cells [97].
The basement membrane is extensively remodeled during
inﬂammatory responses [102, 103] or becomes disorganized
in tumor vasculature [104] and in various cancers [105].
Thus there are a large variety of molecules encountered
during invasion through the basement membrane that
requiretheexpressionofmanydiﬀerentcellsurfaceadhesion
receptors including integrins, cell surface proteoglycans, and
tetraspanins.
4.Integrins
Mammalian integrins generate heterodimeric transmem-
brane glycoprotein adhesion receptor complexes consisting
of α and β subunits (Figure 4)[ 106–109]. Alpha-numeric
designations are applied to 18 known α subunits (α 1–
11,D,E,L,M,V,W,X) and 8 β subunits (β 1–8) available to
form pairs in this class of molecules. Each selective pairing
recognizes a diﬀerent ICAM, ligand, or protein substrate in
the basement membrane or extracellular matrix [110, 111].
The α subunit dictates the ligand speciﬁcity by virtue of
a seven-bladed β-propeller head domain connected to a
leg support structure made of a thigh, a calf-1, a calf-2,
a transmembrane, and a cytoplasmic domain [107, 112].
The β subunit interacts with the cell cytoskeleton and
contains an N-terminal plexin-semaphorin-integrin (PSI)
domain, a hybrid domain, a βI domain, four cysteine-rich
epidermal growth factor (EGF) repeats, a transmembrane,
and a cytoplasmic domain [107, 112]. In many cases, the
N-terminal β-I domain of a β subunit inserts into the β-
propeller domain of an α subunit (α1, α2, α10, α11, αL, αM,
αX, and αD) to form a bulbous-binding headpiece complex
[112].Theformationofintegrinreceptorcomplexesdepends
on divalent cation (i.e., Ca2+,M n 2+,M g 2+) that bind to
metal-ion-dependent adhesion site (MIDAS) motifs in the
α subunits and adjacent to MIDAS (ADMIDAS) motifs in6 International Journal of Cell Biology
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Figure 3: Basement membrane. The basement membrane underlies the typical cellular epithelium or vascular endothelium and consists
of two thin structural layers. One layer is the basal lamina made by epithelial or endothelial cells. The second layer is the reticular lamina
made by ﬁbroblasts. Electron microscope data show that the basal lamina consists of a clear lamina lucida next to epithelial cells and an
opaque lamina densa. The lamina lucida contains integrins, laminins (1, 5, 6 and 10), and collagen XVII, as well as type IV collagen,
and dystroglycans. The lamina densa contains type IV collagen ﬁbers, entactin/nidogen-1, perlecan, and heparan sulfate proteoglycans. The
reticularlaminacontainscollagensI,III,andVandvariousproteoglycans.Invasionthroughthebasementmembranerequirestheexpression
of many diﬀerent cell surface adhesion receptors and matrix degrading enzymes.
β subunits found in the N-terminus of these receptors [107,
111–113]. Together the joined α and β subunit termini form
an N-terminal headpiece [111].
Three conformation states exist for α and β subunit
complexes [114–116]. The ﬁrst conformation is usually
unliganded with a closed headpiece and a bent receptor
structure. In this case, the EGF domains of the β-subunit are
juxtapositioned directly against the calf-1-calf-2 domains in
the support leg of the α-subunit while the headpiece bends
inward toward the plasma membrane [107, 111–113, 116].
Second, the integrin complex headpiece remains closed, but
structuralchangesintheβ-subunitEGFdomainscausethem
to separate from the calf-1-calf-2 domains of the α-subunits
andextendawayfromtheplasmamembrane[111,114–116].
Third, altered conformation in the β6-α7 loops exposes the
ligand-binding site while the β-subunit completely separates
from the calf-1-calf-2 domains in the support leg of the α-
subunit. These cooperative conformational changes in the
heterodimer structures enable the full engagement of a spe-
ciﬁc integrin headpiece with its ligand [111, 114–116]. These
conformational changes can occur during the regulation of
“outside-in signaling” [117, 118] or alternatively “inside-out
signaling” [112, 119].
5. Outside-InSignaling
Similar to conventional cell surface signal transducing recep-
tors, integrins bind ligands and transmit information in
an “outside-in signaling” (Figure 5)[ 111, 112]. “Outside-
in signaling” behavior typically involves the engagement
of integrins with the extracellular matrix or ICAM surface
receptors [111, 118–121]. When external factors bind toInternational Journal of Cell Biology 7
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forming a headpiece complex. The formation of integrin receptor complexes depends on divalent cation (i.e., Ca2+,M n 2+,M g 2+) that bind
to metal-ion-dependent adhesion site (MIDAS) motifs in the α subunits and adjacent to MIDAS (ADMIDAS) motifs in β subunits. Three
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structural changes in the β-subunit EGF domains cause a separation from the calf-1-calf-2 domains of the α-subunits causing an extended
structure. (3) Conformational changes in the β6-α7 loops expose the ligand-binding site along with a complete separation of the β-subunit
from the calf-1-calf-2 domains in the α-subunit. These conformational changes engage the speciﬁc integrin headpiece with its ligand.
exposed ligand binding site on integrins this results in con-
formational changes described in the previous section. Most
ECM proteins exhibit multivalent or recurrent molecular
patterns, which trigger integrin clustering. As cells engage
the repetitive patterns in the ECM, these events occur
simultaneously thereby activating intracellular signals. The
myriad of diﬀerent extracellular signals that cells encounter
in their microenvironment mediates cell polarity, cytoskele-
tal structure, adhesion, migration, invasion, gene expression,
cell survival, and proliferation.
In the case of “outside-in signaling” initiated by ECM
proteins, a single ligand-binding event can trigger integrin
activation, but repetitive regularly spaced molecular patterns
provide a more eﬀective stimulus [122, 123]. This type of
mechanoreception has been explored using nanopatterned
molecular printing techniques that form regular cRGDfK
patch spacings on a polyethylene glycol background matrix
[122–125]. These adhesion-dependent sensory mechanisms
lead to signal transduction inside the cell by the activating
multiple pathways. Focal adhesions are often formed as a
result of cell interactions with the ECM substrata, which
initiate signal transduction via kinase cascades and other
mechanisms.
6. IntegrinsandFocal Adhesions
Focal adhesions were ﬁrst recognized in Rous sarcoma virus-
transformed normal rat kidney cells using an antitumor se-
rumspeciﬁcforpp60src,asaspeckledpatternofﬂuorescence
ontheventralsurface(Figure 5)[126].Focaladhesionkinase
(FAK) is a well-studied integrin-activated protein tyrosine
kinase (PTK) [127, 128]. FAK was identiﬁed as a pp1258 International Journal of Cell Biology
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p190RhoGEF both serve to activate Rho. “Outside-in signaling” transfers integrin-mediated external signals to the inside of cells.“Inside-out
signaling” depends on talin and kindlin. Both talin and kindlin contain FERM (4.1/ezrin/radixin/moesin) domains and a highly conserved
C-terminal F3 domains. Talins bind β integrin, actin through the C-terminus, and also vinculin. Kindlins bind integrins, the cell membrane,
andvariousactinadaptorproteinslikemigﬁlin,orintegrin-linkedkinase(ILK).TalinactivationoccursthroughG-protein-coupledreceptors
thatincreasescytoplasmicCa2+ anddiacylglycerol.ThisactivatesGEFfunctioninconjunctionwithRas-proximate-1/Ras-related-protein-1-
(Rap1-) GTPase. Rap1 then binds to Rap1-GTP-interacting adaptor molecule (RIAM). RIAM recruits talin to the membrane and the α and
β integrin cytoplasmic domains. Kindlin interacts with β integrin cytoplasmic domain stabilizing the activated state of the integrin complex.
“Inside-out signaling” strengthens adhesive contacts and the appropriate force necessary for integrin-mediated cell migration, invasion,
ECM remodeling, and matrix assembly.International Journal of Cell Biology 9
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Figure 6: Linking PGE2 to adhesion, migration, and invasion. Prostaglandin E2 elicits profound changes in tumor cells that result in the
disassociation of cadherin-mediated cell connections. This is accompanied by the establishment/turnover of integrin-mediated interactions
with extracellular matrix during adhesion and subsequent migration and invasion. Stimulation of EP2 or 4 receptors leads to the activation
of adenylate cyclase and results in the production of cyclic adenosine monophosphate (cAMP) from adenosine triphosphate (ATP). The
accumulation of cAMP in the cell cytoplasm activates protein kinase A (PKA) and the phosphorylation of downstream targets. This
accumulation of cAMP can also activate exchange protein activated by cAMP (Epac). The activation of Epac may involve the interactions
withRap1andsubsequentdownstreamsignalsthatinﬂuenceadhesion,migration,andinvasion.TheactivationofEP1andEP3leadstoCa2+
inﬂux and the activation of Rho-mediated signal transduction that inﬂuences cadherin function during the disassociation of cadherin-based
adhesive contacts or integrin interactions with the extracellular matrix contacts.
tyrosine-phosphoprotein in untransformed chicken embryo
cells that increased in pp60v-src-transformed chicken em-
bryo cells [129]. FAK is nonmembrane associated cytoplas-
mic protein that is autophosphorylated on Tyrosine 397 lo-
cated at the juncture of the N-terminal and catalytic do-
mains, which directs SH2-dependent binding of pp60src
[130]. FAK contains a central kinase domain ﬂanked by
FERM (protein 4.1, ezrin, radixin, and moesin homology)
domain at the N-terminus and a focal adhesion targeting
(FAT) sequence at the C-terminus, which drives localization
to focal adhesions [131, 132]. Upon interacting with the cy-
to-plasmic domains of integrins, autophosphorylated FAK
interacts with numerous proteins recruited to focal adhe-
sions. It can aﬀect actin organization through the phospho-
rylation of paxillin [133, 134]. Paxillin phosphorylation by
FAK on tyrosine residues 31 and 118 creates binding sites
for the Src homology-2 (SH2) domains of adaptor proteins
Crk, Csk, and Src [133]. Human enhancer of ﬁlamentation1
(HEF1) and p130 CRK-associated substrate (p130CAS) are
scaﬀold proteins that help to positively regulate Src-FAK-
Crk interactions [135, 136]. Paxillin can also interact with
paxillin kinase linker- (PKL/Git2-) β-pix complexes [137].
β-pix functions as an exchange factor for Cdc42 or serves as
as c a ﬀold protein to promote signaling via the Rho family
GTPase Rac and p21-activated protein kinases-(PAK) [137].
FAK-mediated regulation of Cdc42 and Rac activity asserts
control over the extension of lamellipodia and cell migration
as well as cellular polarization.
As another pathway inﬂuenced by FAK, interactions
with actin-related proteins (ARP2 and ARP3) either occur
directly or are regulated by the Wiskott-Aldrich Syndrome
Protein (WASP) [132]. ARP2/ARP3 closely resembles the
structure of monomeric actin. ARP2/ARP3 complexes serve
as nucleation sites for new actin ﬁlaments [138]. When RP2/
ARP3 complexes bind to the sides of preexisting actin
ﬁlaments, they initiate the polymerization of new ﬁlaments10 International Journal of Cell Biology
at a uniform 70◦ degree-angle during cytoskeletal rearrange-
ments [138]. These molecular activities help organize and
expand growing cytoskeletal meshworks of actin ﬁlaments.
FAK also inﬂuences actin contraction and polarization
through another GTPase protein, Rho. The regulation of
Rho GTPase hydrolysis of GTP (active) to GDP (inactive)
form occurs through the opposing functions of GTPase-
activating proteins (GAPs) or guanine nucleotide exchange
factors (GEFs) [139]. GAPs make GTP a better substrate
for nucleophilic attack thereby lowering the transition state
energy for hydrolysis to GDP, inactivating Rho. In contrast,
GEFs stimulate the release of GDP from Rho and accelerate
the binding of GTP, thereby activating Rho. Among the
Rho-inactivating GAP proteins is one that binds to the C-
terminal domain of FAK, GTPase regulator associated with
FAK (GRAF) to block actin cytoskeleton changes [140].
Another GAP protein, p190RhoGAP, can bind to complexes
with p190RasGAP and FAK that alter the cytoskeleton [141].
In contrast, PDZRhoGEF and p190RhoGEF both serve
to activate Rho. This activation promotes focal-adhesion
turnover and their relocalization within the cell along with
cell migration [142, 143].
7.ProstaglandinsandFocal Adhesion Kinase
“Outside-in”stimulationbyadhesiontoECMalsostimulates
PG pathway activity and FAK activity (Figure 5). When Hela
or NIH3T3 cells are allowed to adhere to ECM, elevations in
COX and PKA stimulate the formation of actin bundles that
contain myosin II and associate with small focal adhesions
and increase cell motility [144]. Similarly, stimulation of
Raw264.7 cells with bovine type I collagen increased cyclic-
AMP response element-binding protein (CREB) binding
to DNA along with COX-2 expression that was reversed
by inhibition of FAK [145]. Fluid shear stress stimulation
of mechanoreceptors and RDGS mediated disruption of
ﬁbronectin adhesions-induced formation of focal adhesions
and promoted the upregulation of COX-2 and PGE2 release
[146].Similarly,mechanostimulationofosteoblastsactivated
FAK and PGE2 release via integrin stimulation, which
increased F-actin ﬁber formation, causing increased cell
stiﬀness [147, 148]. Furthermore, HEF-1 adaptor proteins
thatpositivelyregulateinteractionswithFAKareupregulated
by PGE2 and stimulate cancer cell migration [149].
ProstaglandinshaveaprofoundimpactonFAK,immune
cells,andcancer.Thiscanoccurbystimulationwithavariety
of PGs. For example, in 293-EBNA (Epstein-Barr nuclear
antigen) cells stably expressing prostaglandin F2α (PGF2α)
receptors 1 or 2, stimulation with PGF2α causes morpho-
logical and cytoskeletal changes [150]. The phosphorylation
of FAK occurs in association with Rho-mediated mor-
phological and cytoskeletal changes within two minutes,
highlighting the rapidness of this process [150]. This FAK-
mediated response to PGF2α has also been observed in
HEK293 cells [151] and endometrial adenocarcinoma cells
[152]. Prostaglandin E2 is also a strong stimulus for FAK
activity. In hepatocellular carcinoma cells for example, PGE2
increases the phosphorylation and synthesis of FAK in a
dose-dependent manner [153]. Thus PG ligand binding to
cognate GPCRs can also initiate “inside-out signaling”.
8. Inside-Out Signaling
“Inside-out signaling” depends on a intracellular activa-
tors (Figure 5)[ 119]. These intracellular activators include
proteins such as talin or kindlins [120, 154]. There are
two talin isoforms and three kindlin isoforms identiﬁed
thus far [154]. Both talin and kindlin contain FERM
(4.1/ezrin/radixin/moesin) domains and a highly conserved
C-terminal F3 domain [154]. Talins contain binding sites
for several β integrin cytodomains, a highly conserved C-
terminal actin-binding site and also VBS (vinculin-binding
site) [119, 120]. Kindlins contain β integrin cytodomain-
binding sites in their F3 domains, membrane-binding
domains and a C-terminus that interacts with integrins,
various actin adaptor proteins like migﬁlin, or integrin-
linked kinase (ILK) [120, 154]. The activation process is
thoughttobeginfollowingstimulationofG-protein-coupled
receptors that cause increases in cytoplasmic Ca2+ and
diacylglycerol, followed by GEF activation in conjunction
with Ras-proximate-1/Ras-related protein 1 (Rap1)-GTPase
[119, 120]. Rap1 then binds to Rap1-GTP-interacting
adaptor molecule (RIAM) [155]. RIAM is the believed to
recruit talin to the membrane and the α and β integrin
cytoplasmic domains [119]. Alternatively, talin interacts
with PIPKIγ/PIP2 and then is cleaved by calpain [119].
Kindlin also interacts with the β integrin cytoplasmic
domain stabilizing the activated state of the integrin complex
[119]. “Inside-out signaling” strengthens integrin-mediated
adhesion with extracellular ligands that transfers the appro-
priate force necessary for cell migration, invasion, ECM
remodeling, and matrix assembly [119].
9.Prostaglandins,Integrins,andAngiogenesis
Prostaglandins are known to regulate cellular interactions
with extracellular matrix and angiogenesis as early events
in cancer progression [1]( Figure 6). The overexpression of
COX-2 in rat intestinal epithelial cells was shown to increase
adhesion to ECM and inhibit apoptosis which was reversed
by sulindac sulﬁde (a COX inhibitor) [88]. COX-2 also plays
a key role in endothelial cell migration and tube formation
that relies on interactions with ECM during angiogenesis,
which was reversed by NS398 (a COX-2 inhibitor) [156].
Prostaglandin E2 plays an important role in stimulating
the angiogenic behavior of endothelial cells [157–162]. By
contrast, PGE1 (alprostadil) inhibits angiogenesis in vitro
and in vivo in the murine Matrigel plug assay [163]. Much
of the migratory and invasive behavior of endothelial cells is
regulatedbysignaltransducingintegrinsthatinitiatechanges
in cellular shape, adhesion, and motility. For example,
endothelial cell migration involves αVβ3 (vitronectin) and
α5β1 (ﬁbronectin) integrin function, COX-2, the genesis of
cAMPinvolvingproteinkinaseA[164,165].Thispromotion
ofintegrinαVβ3 integrin-mediatedendothelialcelladhesion,
spreading, migration, and angiogenesis appears to occurInternational Journal of Cell Biology 11
through COX-2-prostaglandin-cAMP-PKA-dependent acti-
vation of the small GTPase Rac [165–167]. Others also
conﬁrmed the involvement of α3β1 receptors [168]. Distinct
integrins such as α6β1 (laminin) or α1β1 and α2β1 (collagen)
receptors are also involved in the migration and invasion of
endothelial cells during angiogenesis [169–175]. These stud-
ieshighlighttheroleofPG-initiatedresponsesbyendothelial
cells that involve integrins during the angiogenesis.
10.Prostaglandins,Integrins,and
Tumor Cell Invasion
Tumor cells also migrate and invade through the basement
membrane in response to stimulation by PGE2 (Figure 6).
For example, PGE2 treatment of LS-174T human colorectal
carcinoma cells leads to increased motility and changes in
cell shape that involves stimulation of the prostaglandin EP4
receptor [176]. In another colon cancer cell line, CaCo2 cell
adhesion to type I collagen via α2β1 integrins was stimulated
by PGE2 and inhibited by COX-2 inhibitors [177]. Similarly,
colon cancer cells expressing β1 integrin levels along with
COX-2 inhibition decreased adhesion and migration on
ECM [178]. In another study using breast cancer cells,
laminin receptor (α3β1) binding to laminin-peptide PA-22
was reduced by PGE2 receptor antagonist (LEO101) [179].
Similarly, the suppression of integrin α3β1 in breast cancer
cells reduced COX-2 gene expression and inhibited tumori-
genesis and invasion [168]. In the case of lung cancer, FN
stimulated cell proliferation through an α5β1 (ﬁbronectin)
integrin-mediated process in conjunction with increases in
COX-2 and PGE2 biosynthesis that was blocked by NS-398
(a COX-2 inhibitor) [180]. The upregulation of COX-2 also
induces tumor cell invasion in models of pancreatic cancer
[181]. Other eicosanoids also inﬂuence integrin-mediated
adhesion and invasion [182, 183]. Collectively, these studies
highlight the importance of PGs during integrin-mediated
adhesion, migration, and invasion through extracellular
matrices by tumor cells.
11.ProstaglandinsandCNNProteins
Prostaglandins also regulate the production of matricellular
proteins of the CCN family (CYR61/CTGF/NOV) that
are emerging as major contributors to chronic inﬂamma-
tory diseases and regulators of ECM [184]. CCN is an
acronym that describes the ﬁrst three protein family mem-
bers identiﬁed out of six total: CYR61/CCN1 (cystein-rich
61;[185]), CTGF/CCN2 (connective tissue growth factor;
[186]), and NOV/CCN3 (nephroblastoma overexpressed;
[187]). The other family members consist of structurally
conservedsecretedmultitaskingWnt-induciblesecretedpro-
teins (WISP-1/CCN4, WISP-2/CCN5, and WISP-3/CCN6)
[188]. Each family member interacts with a speciﬁc subset
of integrins and can be induced by PGE2 depending on the
cellular context [184]. In many instances, cell stimulation
involving CCNs can alter the production of matrix met-
alloproteinases [184]. CCN proteins regulate cell adhesion,
migration, proliferation, and inﬂammatory responses that
are inﬂuenced by PGs [184].
12.ProstaglandinsandCell
Surface Proteoglycans
Proteoglycans are very heavily glycosylated proteins on the
surfacesofcellsthatheavilyinﬂuencecellsignaltransduction
and behavior [94, 189–194]. Proteoglycans exert profound
control over various aspects of wound healing, angiogenesis,
and cancer spreading [192, 195]. The fundamental pro-
teoglycan unit contains a “core protein” and one or more
covalently coupled glycosaminoglycans [190, 191]. Coupling
occurs through a serine residue to a saccharide bridge found
in the glycosaminoglycan. Glycosaminoglycan carbohydrate
structures include chondroitin sulfate, dermatan sulfate,
heparin sulfate, and keratin sulfate. Proteoglycans fall into
two major categories based on size. Small proteoglycans
range in molecular weight between 36 to 66kDa and include
decorin, biglycan, testican, ﬁbromodulin, lumican, synde-
can, and glypican. Large proteoglycans achieve molecular
weights between 136 to 470kDa and include versican,
perlecan, neurocan, and aggrecan within this category. Pro-
teoglycans cooperate dynamically with integrins and growth
factorstolocaladhesionsitesorsignalcomplexestointegrate
of both external and internal signals [196]. Together with
prostaglandins, proteoglycans facilitate adhesion and migra-
tion and tubulogenesis by primary endothelial cells and pro-
motephosphorylationofsignalingmoleculessuchasAktand
Src [94, 197]. Prostaglandins in concert with proteoglycans
also promote the recruitment of stromal cells from the bone
marrow to the developing tumor microenvironment [198,
199]. These include CXCL12, CXCR4, and S100A4 produc-
ingﬁbroblaststhatinvolvesignalingthroughaCOX-2/PGE2-
EP3/EP4-dependent pathway [199]. Similarly, the combined
eﬀect of prostaglandins and proteoglycans regulates the
transition from immature dendritic cells (iDCs) to mature
DCs (mDCs) [198]. In breast cancer cells, prostaglandins
and proteoglycans stimulate invasion across a basement
membrane and induces synthesis of speciﬁc heparin-binding
splice variants of vascular endothelial cell growth factor
(VEGF) [200]. In like fashion, the malignant transformation
of intestinal epithelial cells induces the production of VEGF
that involves Ras pathway activation [160]. Among the
proteoglycans, perlecan in particular plays an integral role
in extracellular matrix deposition in response to PGE2
[201]. Perlecan is also upregulated during tumor-associated
angiogenesis [202], which can be inhibited by decreasing
perlecan synthesis [203]. As a whole, proteoglycans work
together with prostaglandins to regulate tumor growth and
angiogenesis.
13.ProstaglandinsandTetraspanins
Tetraspanins form a family of 33 membrane proteins that
contain 4 transmembrane-spanning domains [204]. They
play important roles in cell adhesion, motility, invasion,
immunity, and tumor progression [205–209]. Among these12 International Journal of Cell Biology
tetraspanins, CD151, CD9, Tspan12, and KITENIN are most
known for their role in cancer [205–208, 210]. Tetraspanin
CD151 interacts with laminin-binding integrins α6β1a n d
α6β4 to regulate signal transduction activity during growth,
migration, invasion, and metastasis [211, 212]. Tetraspanin
CD9incooperationwithcell-surfaceIgsuperfamilyproteins,
EWI-2 and EWI-F acts to suppress tumorigenesis [213–215].
Tspan12 interacts with a disintegrin and metalloprotease
10 (ADAM10) to initiate protumorigenic functions [216,
217]. Also, KAI1 COOH-terminal interacting tetraspanin
(KITENIN) contributes to tumor invasion and metastasis in
human colorectal cancers [210]a n dg a s t r i cc a n c e r[ 218]. In
thecaseofinteractionswithprostaglandins,prostaglandinF2
receptor-associated protein (FPRP) is frequently involved in
binding to cancer cell tetraspanins [219, 220]. However, the
direct regulation of this class of adhesion related molecules
by prostaglandins or eicosanoids remains unknown.
14.Recent AdvancesinProstaglandinand
Adhesion-Based Cancer Therapy
Since (COX-2) is the rate-limiting enzyme in prostaglandin
synthesis, it is an eﬀective intervention point for inhibitors
[221]. It is well documented that elevated COX-2 levels
drive chronic inﬂammation and carcinogenesis [1]. Clinical
and epidemiologic studies clearly demonstrate a signiﬁ-
cant beneﬁt from inhibiting COX-2 in colon cancer [221,
222]. Unfortunately, COX-2 inhibition is associated with
cardiovascular toxicity in a subpopulation of patients at
high risk for cardiovascular disease [221, 222]. Nonetheless,
this pathway remains an excellent target, based on very
strong evidence that the upregulation of COX-2-mediated
inﬂammatory mediators mediates many diﬀerent cancers
[1].
Selective COX-2 inhibition can also initiate a shunt of
AA-based substrates to the 5-lipoxygnease (5-LOX) pathway
[223], Based on these and other ﬁndings, a number of
dual pathway inhibitors have been developed that appear to
exhibit less toxicity [224–227]. Licofelone is a 5-LOX/COX
inhibitor that was developed to treat inﬂammation and
osteoarthritis [228, 229]. In osteoarthritis clinical trials,
licofelone inhibits COX and 5-LOX and has low GI toxi-
city [230, 231]. In another osteoarthritis study, licofelone
reduced osteoarthritis symptoms and less cartilage loss
by MRI than naproxen [232]. Although developed and
tested in osteoarthritis patients, cancer prevention is also
an important target. In a lung carcinogenesis mouse model,
for example, licofelone showed a dose-dependent inhibition
of Cox-2 and 5-Lox and proliferating cell nuclear antigen
(PCNA) staining in concert with an increase in apoptosis
[233]. An overall reduction in GI toxicity in combination
with enhanced anti-inﬂammatory activity makes these new
inhibitorsapromisingclassofcompoundsfortheprevention
and treatment of cancer.
Another approach is to speciﬁcally target speciﬁc points
in the proinﬂammatory and procarcinogenic mPGES1-
PGE2-EP1-4 axis of the COX-2 pathway [221]. Inhibition
of the inducible mPGES-1 has received signiﬁcant attention
[14, 15, 22, 23, 234]. In mouse models, EP(1) and EP(3)
receptor antagonists ONO-8713 and ONO-AE3–240, but
not the EP(4) antagonists ONO-AE3-208 and AH 23848,
inhibited medulloblastoma tumor cell proliferation [235]. In
ApcMin\+ models of colon carcinogenesis, by contrast, the
genetic deletion of mPGES-1 signiﬁcantly protected against
azoxymethane-induced colon cancer [236]. In these studies
genetic the deletion mPGES-1 reduced tumor multiplicity by
∼80% and tumor load by 90% [236]. Also in a syngeneic
mouse model of bone cancer, mPGES-1 enhances tumor
growth and associated pain [237]. These studies emphasize
the importance of mPGES-1 as a target for cancerprevention
and therapy.
As a target further downstream, methods to decrease
the accumulation of PGE2 in tumors are also a potential
target option. In this case, treatment may include enhanc-
ing the metabolic turnover of PGs by 15-PGDH. This
may require upregulation by reversing histone deacetylase-
mediated silencing of 15-PGDH [39]. These approaches are
not as well developed as others but remain viable options for
reducing prostaglandin-associated inﬂammation and cancer
treatment.
As a target even further downstream, the development
of EP selective receptor antagonists has seen extensive
focus [238, 239]. In mouse models, ONO-AE3-208, an EP4
receptor antagonist signiﬁcantly reduced metastasis [240].
Another EP4 antagonist is being tested as an inhibitor of
migraine headache [241]. Selectively targeting the mPGES1-
PGE2-EP1-4 arm of this pathway will likely avoid cardiovas-
cularandGItoxicityattributedtoselectivetargetingofCOX-
2alone.BycombiningtargetingofthemPGES1-PGE2-EP1-4
axis with selective adhesion-based therapy, it may be possible
to signiﬁcantly impact cancer prevention and therapy.
Adhesion-based therapy is generally targeted directly
at surface receptors or the signal transduction pathways
that mediate their activation [242]. In the case of direct
integrin targeting, for example, Phase II clinical trials
with cilengitide, a cyclicized arginine-glycine-aspartic acid-
(RGD-)containing pentapeptide that acts as a αVβ3a n d
αVβ5 integrin antagonist, demonstrated clinical activity with
limited side eﬀects in glioblastoma patients [243, 244].
Based on these clinical results, the ﬁrst Phase III clinical
trial was initiated with an integrin antagonist [243, 244].
Similarly, α5β1 integrins are also inhibited by the RGD ami-
no acid sequence [245, 246], while α4β1 are targeted by
EILDV and REDV sequences [247]. In the case of cadherin
targeting, ADH-1 is a cyclic pentapeptide that disrupts N-
cadherin adhesion complexes that is being used to treat
melanoma [248–250]. In Phase I studies ADH-1 used in
combination with melphalan is well tolerated after isolated
limb perfusion to treat regionally advanced melanoma. This
approach using ADH-1 is believed to help overcome mel-
anoma chemoresistance [250]. As we enter an era of per-
sonalized cancer therapy, using peptides to target speciﬁc
adhesion receptors may be a viable adjuvant for selective
targeting.
Targeting the signal transduction pathways downstream
ofadhesion receptorsignaling involves avariety ofmolecular
targets. These include the kinases, phosphatases GAP, GEF,International Journal of Cell Biology 13
Rho family GTPases, adapter molecules, and scaﬀolding pro-
teins among others. In the case of kinase targets, Src is a
good candidate [251]. Src protein family members are useful
because they serve as starting points for multiple signaling
cascades involved in extracellular sensory activity [251]. This
class of drugs includes the following: Bosutinib, AZD0530,
and Dasatinib that target both cadherin/p120 catenin which
aﬀects adherens junctions [251]. Simultaneously, these com-
pounds can aﬀect integrin/FAK p130Cas, paxillin, and Rho,
a downstream that aﬀects interactions with ECM [251].
Preclinically for instance, AZD053 prevents phosphorylation
of paxillin and FAK and suppresses metastasis in vivo [251].
Another eﬀective kinase adhesion target is FAK [252,
253]. One of the most promising FAK inhibitors is PND-
1186,whichblocksFAKTyr-397phosphorylation[254–256].
In vitro, PND-1186 blocks FAK tyrosine phosphorylation
while activating caspase-3 and initiating breast tumor cell
apoptosis [255]. PND-1186 has also been tested in vivo
and inhibits the growth of orthotopic breast carcinoma
mousemodels[254].Targetingkinasemoleculesortheother
intracellular signal pathway molecules may exhibit oﬀ-target
eﬀects that can be beneﬁcial or cause unwanted side eﬀects.
Identifying patients with limited risk that will derive the
most beneﬁt from a given approach is essential to successful
treatment.
In summary, targeting cell adhesion holds great promise
for cancer therapy. As we learn more about individualizing
cancer therapy, identifying patients that would receive the
most beneﬁt will help to direct targeting. For example,
targetingspeciﬁcadhesionpathwayscouldbecombinedwith
inhibiting the mPGES1-PGE2-EP1-4 axis in patients that
also have elevated COX-2 in their tumors or elevated PGE2
metabolites in their blood and/or urine. This approach may
serve as an eﬀective means of personalizing treatment or
providing speciﬁcally targeted adjuvant therapy.
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